Plain-English translation of NCT06347653 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to treating a rare type of lymphoma called nodal T-follicular helper cell lymphoma. The treatment combines a new drug called linperlisib with standard chemotherapy, followed by a stem cell transplant and then continued use of the medication alone. Researchers want to see if this combination approach works better than current treatments for newly diagnosed patients.
Nodal T-follicular helper cell lymphoma is a rare blood cancer that is difficult to treat. This trial exists to find out whether adding the new medication to standard chemotherapy and stem cell transplant can improve outcomes and help patients live longer without their cancer returning.
You likely qualify if…
You likely don't qualify if…
You would receive the new medication combined with chemotherapy over several cycles of treatment at a hospital or cancer center. After this, you would undergo a stem cell transplant, where your own blood-forming stem cells are collected, you receive high-dose chemotherapy, and then your cells are returned to your body to help rebuild your blood system. Following the transplant, you would continue taking the medication by mouth as maintenance therapy. The trial involves multiple visits to the hospital for blood tests, scans, and monitoring of your health and how well you're responding to treatment.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China